Abstract
Recently an increase in the number of patients suffering from vertigo has been noted in our clinic. Furthermore, it has been reported that an insufficiency of cerebral circula tion is important in the pathogenesis of vertigo. Antiplatelet drugs are known to improve insufficiency of the circulation. In this paper, an antiplatelet drug was administrated to the patients with vertigo. Some parameters of coagulation-fibrinolysis system and platelet function were measured before and after the administration of an antiplatelet drug. The effect of antiplatelet drug on vertigo was determined by both patient's subjective reports and objective laboratory findings. Fibrinogen (Fg) content was measured according to QUICK'S method. Plasminogen (Plg), α2-macroglobulin (α2-M), α1-antitrypsin (α1-AT), and Cl-inactivator (Cl-inact.) content were measured according to the single radial immunodiffusion method. FDP content was determined using latex aggregation. a2-plasmin inhibitor (α2-PI) activity and antithrombin-III (AT-III) activity were determined using a synthetic substrate. Platelet aggregation was determined using an aggregometer. These parameters were determined before and after the administration of an antiplatelet drug (Dilazep) and these determinations were compared with those of healthy adults. The results obtained from this study were as follows: 1) Fg, Plg, FDP, α2-M, α1-AT, Cl-inact. content before and after the administration of Dilazp compared with those of healthy adults were not significantly different. 2) α2-PI activity and AT-III activity before and after the administration of Dilazep were significantly reduced (both at p<0.001) in the vertigo group compared with those of healthy adults. 3) Platelet aggregation before and after the administration of Dilazep was compared with those of healthy adults, and then, ADP and collagen-induced aggregation of platelet significantly enhanced (p<0.001). 4) After the administration of Dilazep, improvement of subjective symptoms and laboratory findings were seen in 78.8% of the patients with vertigo. From these results, it is suggested that the administration of an antiplatelet drug (Dilazep) is useful in treating patients with vertigo because of improvement of the cerebral circulation.
